Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - ranolazine - prolonged-release tablet - ranolazine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - ranolazine - prolonged-release tablet - ranolazine

Μάλτα - Αγγλικά - Medicines Authority

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - prolonged-release tablet - verapamil hydrochloride 240 mg - calcium channel blockers

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - ibuprofen - prolonged-release tablet - propionic acid derivatives; ibuprofen

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

actavis elizabeth llc - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - tablet - 500 mg - metformin hydrochloride tablets, as monotherapy, are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. metformin is indicated in patients 10 years of age and older. metformin may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults (17 years of age nd older). metformin hydrochloride tablets are contraindicated in patients with: 1. renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 mg/dl [males], ≥ 1.4 mg/dl [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnlngsand precautions). 2. congestive heart failure requiring pharmacologic treatment. 3. known hypersensitivity to metformin hydrochloride. 4. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. metformin should

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - metformin hydrochloride - modified-release tablet - 1gram

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - metformin hydrochloride - modified-release tablet - 1gram

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

actavis pharma, inc. - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. important limitations of use metformin hydrochloride extended-release tablets should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. metformin hydrochloride extended-release tablets are contraindicated in patients with: - severe renal impairment (egfr below 30ml/min/1.73 m2 ) [see warnings and precautions (5.1)] . severe renal impairment (egfr below 30ml/min/1.73 m2 ) [see warnings and precautions (5.1)] . - known hypersensitivity to metformin hydrochloride. known hypersensitivity to metformin hydrochloride. - acute or chronic metabolic acidosis, including diabetic ketoacidosis. diabetic ketoacidosis should be treated with insulin. acute or chronic metabolic acidosis, including diabetic ketoacidosis. diabetic ketoacidosis should be treated wit

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

actavis pharma, inc. - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin hydrochloride extended-release tablets are contraindicated in patients with: 1. severe renal impairment (egfr below 30 ml/min/1.73 m2 ) (see warnings  and precautions ). 2. known hypersensitivity to metformin hydrochloride. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. 

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

actavis pharma, inc. - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin hydrochloride extended-release tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1) ]. - hypersensitivity to metformin. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary   limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see data] . there are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [see clinical considerations ]. no adverse developmental effects were observed when